Cymabay offering
WebJan 30, 2024 · CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a... WebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public...
Cymabay offering
Did you know?
WebCymaBay is selling 15,625,000 shares of common stock and pre-funded warrants to purchase 3,125,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $4.00 per share, and the pre-funded warrants are being sold at a public offering price of $3.9999 per underlying share. WebCymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares 24 Jan CymaBay Announces Pricing of Public Offering …
WebThe offering is expected to close on February 1, 2024, subject to the satisfaction of customary closing conditions. ... The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). WebJan 23, 2024 · CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size …
WebMar 17, 2024 · Overall, our net loss for the quarters ended December 2024 and 2024 was $26.6 million and $26.5 million or $0.30 and $0.34 per share respectively and net loss for the years ended December 2024 and ... WebJan 24, 2024 · The gross offering proceeds to CymaBay from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being …
WebJan 23, 2024 · CymaBay Therapeutics (NASDAQ:CBAY) +7.6% aftermarket on Monday announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
WebJul 14, 2015 · CymaBay anticipates using the net proceeds from the offering for general corporate purposes, including clinical trials, research and development, capital expenditures and working capital. Piper... chiltern school houghton regis term datesWebNov 17, 2024 · NEWARK, Calif., Nov. 17, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative... chiltern school of motoring gamlingaychilterns cilWebJan 24, 2024 · CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $7.00 per share, and the pre-funded warrants are being sold at a public offering price of $6.9999 per underlying share. grade 8 technology wedgesWebJan 30, 2024 · Additional risks relating to CymaBay are contained in CymaBay's filings with the SEC, including without limitation its Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 14, 2024, and other documents subsequently filed with or furnished to the SEC, including the final prospectus supplement related to the … grade 8 technology worksheetsWebMar 6, 2024 · CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. chilterns chalkWebNov 17, 2024 · NEWARK, Calif., Nov. 17, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative... chiltern school wokingham